Minerva Neurosciences Inc (NERV) — Cash Flow-to-Debt Ratio
Minerva Neurosciences Inc (NERV) has a Cash Flow-to-Debt Ratio of -15.59x as of March 2026, meaning its operating cash flow of $-5.43 Billion could theoretically repay -16% of its total liabilities ($348.04 Million) in one year. See financial flexibility index of Minerva Neurosciences Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Minerva Neurosciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Minerva Neurosciences Inc across 14 annual periods. For the full cash flow conversion analysis, see Minerva Neurosciences Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Minerva Neurosciences Inc (2012–2025)
Year-by-year debt coverage analysis for Minerva Neurosciences Inc. Check NERV cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -56.60x | $-13.51 Billion | $238.72 Million | ▼ -18091.0% |
| 2024 | -0.31x | $-19.55 Million | $62.84 Million | ▼ -79.6% |
| 2023 | -0.17x | $-14.78 Million | $85.36 Million | ▲ +47.2% |
| 2022 | -0.33x | $-24.65 Million | $75.11 Million | ▲ +7.8% |
| 2021 | -0.36x | $-24.60 Million | $69.15 Million | ▲ +94.8% |
| 2020 | -6.81x | $-33.82 Million | $4.96 Million | ▼ -680.0% |
| 2019 | -0.87x | $-43.43 Million | $49.72 Million | ▼ -1.8% |
| 2018 | -0.86x | $-41.94 Million | $48.87 Million | ▼ -1545.7% |
| 2017 | 0.06x | $3.09 Million | $52.10 Million | ▲ +106.2% |
| 2016 | -0.95x | $-25.69 Million | $26.96 Million | ▼ -7.0% |
| 2015 | -0.89x | $-24.27 Million | $27.26 Million | ▲ +58.0% |
| 2014 | -2.12x | $-35.96 Million | $16.95 Million | ▼ -783.4% |
| 2013 | -0.24x | $-2.16 Million | $9.00 Million | ▲ +95.0% |
| 2012 | -4.77x | $-908.54K | $190.29K | — |